We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

125 hedge funds and large institutions have $246M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 62 increasing their positions, 22 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

44,067% more call options, than puts

Call options by funds: $1.32M | Put options by funds: $3K

182% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 22

4% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 25

2% less funds holding

Funds holding: 128 → 125 (-3)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

64% less capital invested

Capital invested by funds: $690M → $246M (-$444M)

Holders
125
Holders Change
-3
Holders Change %
-2.34%
% of All Funds
2.01%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
24
Increased
62
Reduced
22
Closed
25
Calls
$1.32M
Puts
$3K
Net Calls
+$1.32M
Net Calls Change
-$5.32M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$36.9M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.79M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$3.7M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.64M
5
Millennium Management
Millennium Management
New York
+$1.43M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$26.8M
2
APM
Avidity Partners Management
Texas
-$23.5M
3
FLAM
First Light Asset Management
Minnesota
-$12.5M
4
LGM
Logos Global Management
California
-$11.1M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Column Group
California
$91M – – –
EC
2
EcoR1 Capital
California
$32.3M +$36.9M +5,894,410 +1,089%
Vanguard Group
3
Vanguard Group
Pennsylvania
$22.5M +$3.7M +589,852 +15%
BlackRock
4
BlackRock
New York
$20.9M +$584K +93,185 +2%
SG
5
StepStone Group
California
$7.9M – – –
RCMNY
6
Rubric Capital Management (New York)
New York
$4.4M – – –
N
7
Nuveen
North Carolina
$3.8M +$119K +18,943 +3%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$3.76M +$71.5K +11,408 +2%
EC
9
Euclidean Capital
New York
$3.75M – – –
State Street
10
State Street
Massachusetts
$3.54M -$947K -151,024 -18%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$3.38M +$3.79M +604,515 +881%
Morgan Stanley
12
Morgan Stanley
New York
$3.32M +$721K +114,974 +21%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$2.91M +$3.64M +581,223 New
JP Morgan Chase
14
JP Morgan Chase
New York
$2.85M +$205K +32,642 +6%
BC
15
Boxer Capital
California
$2.51M – – –
Millennium Management
16
Millennium Management
New York
$2.3M +$1.43M +227,384 +99%
Goldman Sachs
17
Goldman Sachs
New York
$1.91M +$288K +46,019 +14%
CS
18
Candriam SCA
Luxembourg
$1.89M +$577K +92,112 +32%
JRP
19
Jasper Ridge Partners
California
$1.75M +$185K +29,500 +9%
Northern Trust
20
Northern Trust
Illinois
$1.73M +$35.2K +5,608 +2%
Renaissance Technologies
21
Renaissance Technologies
New York
$1.72M +$434K +69,300 +25%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$1.65M +$268K +42,800 +15%
Charles Schwab
23
Charles Schwab
California
$1.65M +$84.1K +13,415 +4%
Two Sigma Investments
24
Two Sigma Investments
New York
$1.4M +$121K +19,250 +7%
Deutsche Bank
25
Deutsche Bank
Germany
$1.22M -$119K -18,996 -7%
1
2 3 4 5

NGM Hedge Fund Activity: Q4 2022 in Review

125 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2022, worth a combined $246M — down 64% from $690M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of NGM and 24 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 62 added.

The largest buyer was EcoR1 Capital, adding an estimated $36.9M. The largest seller was Fidelity Investments, cutting an estimated $26.8M.

  • 125 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2022, down from 128 in Q3 2022.
  • Funds reported $246M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2022, down 64% quarter-over-quarter.
  • 24 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2022 and 25 closed out, a net change of -1 holder.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2022 was EcoR1 Capital, an estimated $36.9M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $26.8M sold.

Based on aggregated 13F filings for Q4 2022.